



ASX Announcement and Media Release

(ASX : SIE)

Profit Sharing for Human Insulin in China

Singapore, July 15th, 2009. – In response to market enquiry following the company’s announcement on July 10th 2009, SciGen Ltd (“SciGen”) has set out below further information regarding the Profit Sharing Agreement between “SciGen” and its Polish holding company Bioton SA (“Bioton”) for the distribution of SciGen’s Human Insulin product, Scilin[®] in China.

SciGen announces the following additional information on the agreement with Bioton

- 1 The subject matter of the agreement is apportionment of the profit resulting from the exclusive agreement on supplies and distribution of insulin on the territory of the People’s Republic of China concluded between the SciGen, Bioton and Bayer Healthcare Company Ltd (“**BHC**”), which was reported by the Company on July 10th 2009.
- 2 The parties have agreed that in connection with SciGen granting to BHC an exclusive right for commercializing the insulin produced by Bioton on the territory of PRC, SciGen shall be entitled to a share in the profit resulting from the supply of insulin by the Bioton on the basis of the agreement with BHC.
- 3 The SciGen estimates that the aggregate revenue of its share in the profits from the agreement with Bioton, through the entire period of its duration shall amount to between USD 225 -270 million.
- 4 The agreement has been concluded for the period of 15 years which corresponds to the term of the agreement with BHC.

About SciGen

SciGen Ltd is 90.54% owned by Bioton S.A, It is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in the Australia, S.Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China. Bioton S.A. is the supplier of Insulin to SciGen.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Adam Allerhand Chairman & CEO SciGen Ltd +65 6779 6638